Vitenskapelig artikkel

Cerebrospinal fluid proteome shows disrupted neuronal development in multiple sclerosis

Mosleth, Ellen F.; Vedeler, Christian Alexander; Liland, Kristian Hovde; McLeod, Anette; Bringeland, Gerd Haga; Kroondijk, Liesbeth; Berven, Frode Steingrimsen; Lysenko, Artem; Rawlings, Christopher J.; El-Hajj Eid, Karim; Opsahl, Jill Anette; Gjertsen, Bjørn Tore; Myhr, Kjell-Morten; Gavasso, Sonia

Publikasjonsdetaljer

Tidsskrift: Scientific Reports, vol. 11, 2021

Internasjonale standardnumre:
Trykt: 2045-2322
Elektronisk: 2045-2322

Open Access: gold

Lenker:
ARKIV
DOI

Despite intensive research, the aetiology of multiple sclerosis (MS) remains unknown. Cerebrospinal fluid proteomics has the potential to reveal mechanisms of MS pathogenesis, but analyses must account for disease heterogeneity. We previously reported explorative multivariate analysis by hierarchical clustering of proteomics data of MS patients and controls, which resulted in two groups of individuals. Grouping reflected increased levels of intrathecal inflammatory response proteins and decreased levels of proteins involved in neural development in one group relative to the other group. MS patients and controls were present in both groups. Here we reanalysed these data and we also reanalysed data from an independent cohort of patients diagnosed with clinically isolated syndrome (CIS), who have symptoms of MS without evidence of dissemination in space and/or time. Some, but not all, CIS patients had intrathecal inflammation. The analyses reported here identified a common protein signature of MS/CIS that was not linked to elevated intrathecal inflammation. The signature included low levels of complement proteins, semaphorin-7A, reelin, neural cell adhesion molecules, inter-alpha-trypsin inhibitor heavy chain H2, transforming growth factor beta 1, follistatin-related protein 1, malate dehydrogenase 1 cytoplasmic, plasma retinol-binding protein, biotinidase, and transferrin, all known to play roles in neural development. Low levels of these proteins suggest that MS/CIS patients suffer from abnormally low oxidative capacity that results in disrupted neural development from an early stage of the disease.